Skip to content
Calculator
Guide

VIP and 'MCAS stacks': what's studied (aviptadil) and what's improvised

Last updated: October 27, 2026 · 9 min read · By the Grey Peptides Editorial Board

A parent helping a child use a nebulizer at home
Photo by cottonbro studio on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • Aviptadil, the drug form of VIP, was tested in critical COVID-19. The largest trial stopped for futility 5, and it has no FDA approval 3.
  • VIP is promoted for mast cell activation syndrome (MCAS), but in human mast cells in the lab it triggered degranulation, the opposite of what an MCAS treatment should do 9.
  • We found no clinical trial of VIP in MCAS. 'MCAS stacks' combining VIP with other peptides are improvised, not studied.
  • VIP can also trigger migraine attacks in people prone to them 15.

What VIP is

Vasoactive intestinal peptide is a 28-amino-acid neuropeptide found throughout the central and peripheral nervous system and released by nerve and immune cells; it acts as a neurotransmitter, an immune regulator, a blood-vessel dilator and a stimulant of secretion (review) 1. Aviptadil is its synthetic drug form 2. As of October 27, 2026, Drugs@FDA holds no application for aviptadil 3. For compounding, FDA lists vasoactive intestinal peptide in Category 1 of its 503A nominations, substances still under evaluation 4; that is a review status, not an approval.

This page looks at VIP nasal sprays and 'stacks' promoted for mast cell activation syndrome, long COVID and other inflammatory conditions. We found no published study that gave VIP to people as a nasal spray (PubMed search, October 27, 2026). Those uses are where the evidence runs out.

Aviptadil in COVID-19: the trials

During the pandemic, VIP's effects on lung cells in laboratory studies made aviptadil a candidate for severe COVID-19. In a 2022 trial of 196 patients at ten US hospitals, three days of intravenous aviptadil did not meet the primary endpoint of being alive and free of respiratory failure at day 60; survival at day 60 was better as a secondary measure, with less interleukin-6 release by day 3. One author was affiliated with NRx Pharmaceuticals, the drug's developer (randomised trial) 2.

The larger test was TESICO, a randomised trial comparing aviptadil and remdesivir with placebo in patients with COVID-19 acute hypoxaemic respiratory failure, a group whose 60-day mortality the investigators put at 30% to 50%; 94% of those in the aviptadil comparison were in intensive care, and the trial had NIH support. Intravenous aviptadil was given as a 12-hour infusion on three days, or placebo. The trial was stopped for futility: the odds of a better day-90 outcome were 1.11, and 38% of the aviptadil group against 36% of the placebo group had died by day 90 (randomised trial) 5.

A small 2025 trial of inhaled aviptadil reported faster discharge (7.8 against 10.0 days on average), less breathlessness at day 7 and more improvement in lung scans, with deaths of 5.1% against 12.2%; the trial enrolled 80 patients at nine centres, with no drop-outs from side effects (randomised trial) 6. A small positive trial after a large negative one needs confirmation before it changes the picture.

Where VIP has been used as a medicine

COVID-19 was not VIP's first medical outing. Combined with phentolamine as an injection into the penis, aviptadil has been used for erectile dysfunction. In a 2025 single-centre review of 308 men for whom the standard injection, alprostadil, had failed or was too painful, 59% found the aviptadil-phentolamine injection effective at three months; facial flushing affected 22.5%, and one man had priapism (retrospective study) 7. That use, an injection given for a local effect, says nothing about nasal sprays sold for inflammation.

Inhaled VIP has also been explored in lung disease. In an open phase 2 study, 20 people with active sarcoidosis inhaled VIP for four weeks; it was well tolerated and reduced the inflammatory signal TNF-alpha from cells washed out of their lungs, while increasing regulatory T cells (open-label study) 8. Without a control group, it shows biological activity in the lung, not clinical benefit, and it has not led to an approved inhaled product.

Long COVID claims

VIP is also marketed for long COVID. The only aviptadil trial we found that followed patients after hospital was the small 2025 inhaled study, which measured lung scans at day 28 in people hospitalised with COVID-19, not people with long COVID 6. We found no trial of VIP in long COVID. Given that the large intravenous trial in acute disease was negative 5, the long COVID claims rest on extrapolation rather than evidence.

VIP and mast cells: the opposite of the marketing

MCAS is a condition in which mast cells, immune cells that store histamine and other mediators, release them too readily, causing flushing, hives, gut symptoms and more. A treatment for MCAS should calm mast cells. VIP appears to do the reverse. In a 2008 study of human mast cells grown in the laboratory, VIP and substance P made both primary mast cells and a human mast cell line degranulate, releasing their contents, and VIP strongly induced production of inflammatory chemokines (laboratory study) 9.

The likely route is a receptor called MRGPRX2. A 2015 review describes it as expressed on mast cells and sensory nerves, interacting with peptides including substance P and VIP, and linked to mast cell degranulation (review) 10. In mice, mast cells limited the toxicity of high concentrations of VIP and of a structurally similar venom peptide by breaking them down (animal study) 11, another sign that VIP and mast cells are closely entangled. None of this proves that a VIP nasal spray worsens MCAS in people. It does mean the claim that VIP calms mast cells has the laboratory evidence against it.

QuestionWhat the evidence shows
Did intravenous aviptadil help critical COVID-19?No clear benefit: TESICO stopped for futility; an earlier trial missed its primary endpoint
Did inhaled aviptadil help?A small 2025 trial reported faster discharge; not confirmed in a large trial
Does VIP calm mast cells?In human mast cells in the lab, VIP triggered degranulation
Has VIP been tested in MCAS?We found no treatment trial
Can VIP trigger migraine?Yes: VIP infusion provoked attacks in 15 of 21 people with migraine

Has VIP been tested in MCAS?

We searched PubMed on October 3 and again on October 27, 2026 for studies of VIP in mast cell activation syndrome and found no treatment trial. MCAS itself is a field of active debate: a 2026 commentary by proponents of the broader 'consensus-2' diagnostic criteria, some of them at a private mast-cell clinic, argues that more restrictive criteria underdiagnose it and that appropriate therapy can greatly improve quality of life (commentary) 12, while other experts favour stricter criteria. Either way, treatment for MCAS is managed by clinicians who know mast cell disease, with medicines whose evidence is established for it; VIP is not among them in anything we found.

Why MCAS is easy to over-read, and to miss

Mast cell activation is common; mast cell activation syndrome is a specific diagnosis. A 2026 review of mast cell activation disorders notes that diagnosing MCAS requires elevated serum tryptase or elevated urinary mast-cell mediator metabolites and/or involvement of several organs, that mast cell activation is present in many conditions that do not qualify, and that patients are often mistaken for other conditions with similar symptoms that worsen with stress (review) 13. It calls for better-defined criteria and more effective inhibitors for treatment 13.

That matters for anyone drawn to peptide stacks. Symptoms labelled MCAS online may have other causes that need different treatment, and a self-diagnosis treated with an unproven peptide can delay finding them. Equally, the commentary from proponents of broader criteria argues that genuine MCAS is often missed and can be treated effectively 12. Both views point to the same practical step: assessment by a clinician who knows mast cell disease.

What 'MCAS stacks' are

'MCAS stacks' pair VIP with other peptides, such as KPV, thymosin alpha-1 or BPC-157. We found no study of any of these in mast cell disease; for KPV, FDA says it has not identified any human exposure data at all 14. A stack of unproven peptides is not more proven than its parts, and combining them adds unknown interactions. Our blend pages explain why combinations are harder to judge than single compounds.

VIP and migraine

VIP is a potent blood-vessel dilator, and in people with migraine it can trigger attacks. In a 2021 provocation study, VIP infusion was followed by migraine attacks in 15 of 21 people against 1 of 21 on placebo, attacks resembling their usual ones, with greater headache intensity and artery widening Two of its authors were from Novartis (randomised crossover study) 15. Anyone with migraine should know that before trying a VIP product. The related peptide PACAP behaves similarly, which our PACAP entry covers.

Status, as of October 27, 2026

Aviptadil is investigational, with no application on Drugs@FDA 3, and VIP is in Category 1 of FDA's 503A nominations, under evaluation rather than approved 4. For athletes, VIP is not named on WADA's 2026 or 2027 List; the List's S0 class prohibits any substance with no current approval by any government health authority for human therapeutic use, and whether that reaches VIP depends on approvals outside the US that we have not verified 16. Our guide to 'research use only' explains what those labels do and do not mean.

If you have symptoms you think are MCAS

Flushing, hives, swelling, gut upset, palpitations and fatigue have many causes. The review of mast cell disorders stresses that the diagnosis of MCAS rests on measurable evidence, such as raised tryptase or urinary mediator metabolites, and on involvement of several organs, and that many look-alike conditions exist 13. The practical route is an assessment by an allergist or immunologist familiar with mast cell disorders, ideally with tests timed to symptom flares, before any treatment is chosen. If a peptide product is already part of your routine, tell them, along with when you started it; our guide to talking to your doctor about peptides includes a script. If you have sudden swelling of the face or throat, trouble breathing or faintness, treat it as an emergency.

Questions to ask before using VIP

  • Has a clinician confirmed the diagnosis, and what established treatments have been tried?
  • Is there any trial of VIP in my condition? For MCAS, we found none.
  • Do I have migraine? VIP can trigger attacks.
  • Given that VIP activated human mast cells in the laboratory, what is the rationale for using it to calm them?
  • What exactly is in the product, and is it sterile?

The bottom line

Aviptadil, the drug form of VIP, had its big test in critical COVID-19 and did not succeed; it is not approved. VIP is sold for MCAS, but no trial has tested that, and in human mast cells in the laboratory VIP triggered the very release MCAS patients want to stop. 'MCAS stacks' are improvised combinations of peptides with little human evidence. For mast cell disease, the evidence-based route runs through a clinician and established medicines.

Frequently asked questions

What is VIP peptide?

Vasoactive intestinal peptide, a 28-amino-acid hormone and nerve signal that relaxes smooth muscle and widens blood vessels. Its drug form, aviptadil, is investigational.

Did aviptadil work for COVID-19?

The largest trial, TESICO, stopped for futility, with day-90 deaths of 38% versus 36% on placebo. A smaller earlier trial missed its primary endpoint; a small inhaled trial reported faster discharge.

Does VIP help mast cell activation syndrome?

No trial has tested it. In human mast cells in the laboratory, VIP triggered degranulation, the opposite of what an MCAS treatment should do.

Can VIP cause migraines?

Yes. In a provocation study, VIP infusion triggered migraine attacks in 15 of 21 people with migraine against 1 of 21 on placebo.

Is aviptadil FDA-approved?

No. As of October 27, 2026, Drugs@FDA holds no application for aviptadil. Vasoactive intestinal peptide is in Category 1 (under evaluation) of FDA's 503A compounding nominations.

Sources

  1. Delgado, M., et al. (2013). Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids, 45(1), 25-39. PMID: 22139413
  2. Youssef, J. G., et al. (2022). The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial. Crit Care Med, 50(11), 1545-1554. PMID: 36044317
  3. U.S. Food and Drug Administration. Drugs@FDA via openFDA: no application for aviptadil or vasoactive intestinal peptide. Queried October 27, 2026. Cited without a link.
  4. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A: Category 1, Bulk Drug Substances Under Evaluation, lists Vasoactive Intestinal Peptide (updated May 14, 2026). Read October 27, 2026. FDA
  5. Brown, S. M., et al. (2023). Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. Lancet Respir Med, 11(9), 791-803. PMID: 37348524
  6. Esendagli, D., et al. (2025). Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19. Med Princ Pract, 34(2), 191-200. PMID: 39870064
  7. Al-Mitwalli, A., et al. (2025). Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction. J Sex Med, 22(5), 726-730. PMID: 40192471
  8. Prasse, A., et al. (2010). Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med, 182(4), 540-8. PMID: 20442436
  9. Kulka, M., et al. (2008). Neuropeptides activate human mast cell degranulation and chemokine production. Immunology, 123(3), 398-410. PMID: 17922833
  10. Wu, H., et al. (2015). The Origin, Expression, Function and Future Research Focus of a G Protein-coupled Receptor, Mas-related Gene X2 (MrgX2). Prog Histochem Cytochem, 50(1-2), 11-7. PMID: 26106044
  11. Akahoshi, M., et al. (2011). Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice. J Clin Invest, 121(10), 4180-91. PMID: 21926462
  12. Afrin, L. B., et al. (2026). Progress in mast cell activation syndrome: the global consensus-2 diagnostic criteria at six years. Diagnosis (Berl), . PMID: 42240520
  13. Theoharides, T. C., et al. (2026). Mast cell activation disorders: mechanisms, comorbidities and look-alike. Expert Rev Clin Immunol, 22(7), 767-787. PMID: 42405823
  14. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, withdrawn-nominations table, KPV: FDA has not identified any human exposure data (content current as of April 22, 2026). Read October 27, 2026. FDA
  15. Pellesi, L., et al. (2021). Effect of Vasoactive Intestinal Polypeptide on Development of Migraine Headaches: A Randomized Clinical Trial. JAMA Netw Open, 4(8), e2118543. PMID: 34357396
  16. World Anti-Doping Agency. The 2026 Prohibited List, section S0 (non-approved substances); VIP and aviptadil are not named in the 2026 List or in the 2027 List (in force January 1, 2027). Read October 27, 2026. WADA 2026 List

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead